Korlym (mifepristone) — Highmark
Endogenous Cushing’s syndrome with type 2 diabetes mellitus or glucose intolerance in adults who have failed surgery or are not candidates for surgery
Initial criteria
- age ≥ 18 years
- Diagnosis of endogenous Cushing’s syndrome (ICD-10: E24)
- Member is not a candidate for surgery OR has experienced therapeutic failure to surgery
- Member has type 2 diabetes mellitus (ICD-10: E11) AND has experienced therapeutic failure to one previous pharmacologic therapy for type 2 diabetes OR is taking Korlym in addition to pharmacologic therapy for type 2 diabetes OR member has glucose intolerance
Reauthorization criteria
- Prescriber provides documentation that the member has experienced improvement in hyperglycemia following Korlym administration
Approval duration
12 months